Tumor physiology and delivery of nanopharmaceuticals

Area of Science:

• Nanomedicine and Drug Delivery
• Oncology
• Biotechnology

Background:

• Significant progress in nanopharmaceutical development (e.g., phospholipid, polymer-based) for cancer treatment over recent decades.
• Current nanopharmaceutical approaches face challenges in selectively delivering drugs to solid tumors and minimizing off-target effects.
• Physiological barriers within tumors often limit the efficacy of nanopharmaceutical therapies.

Purpose of the Study:

• To review critical challenges in nanopharmaceutical drug delivery for cancer.
• To discuss the physiological role and unique anatomical/functional nature of solid tumors in nanopharmaceutical transport.
• To provide an overview of strategies for overcoming physiological barriers and leveraging tumor biology for enhanced therapeutic outcomes.

Main Methods:

• Literature review focusing on nanopharmaceutical delivery to solid tumors.
• Analysis of tumor physiology, including anatomical structure and transport dynamics.
• Exploration of methods to overcome physiological barriers and exploit tumor pathogenesis.

Main Results:

• Solid tumors present unique physiological barriers that impede effective nanopharmaceutical delivery.
• Tumor-specific anatomical structures and functions influence drug transport and distribution.
• Strategies exist to overcome these barriers and utilize tumor biology for therapeutic advantage.

Conclusions:

• Understanding and overcoming tumor-specific physiological barriers are crucial for advancing nanopharmaceutical cancer therapy.
• Exploiting tumor pathogenesis offers promising avenues for improving drug targeting and efficacy.
• Future nanopharmaceutical development must address these challenges to realize their full clinical potential.